Market Overview:
The global pravastatin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as an increase in the prevalence of cardiovascular diseases, rising awareness about cholesterol management, and increasing demand for generic drugs. Based on type, the global pravastatin market is segmented into 10mg tablet, 20mg tablet, 40mg tablet, and 80mg tablet segments. The 10mg tablet segment is expected to account for the largest share of the global pravastatin market in 2018. Based on application, the global pravastatin market is segmented into adults and children segments.
Product Definition:
Pravastatin is a drug used to lower cholesterol levels. It belongs to the class of drugs called statins, which work by inhibiting the enzyme HMG-CoA reductase, preventing cholesterol from being made in the liver.
10mg tablet:
The drug has no effect on cancer or HIV infection. It works by decreasing the amount of cholesterol carried in the blood stream and hence reduces the risk of a heart attack or stroke. This drug also prevents another person's cholesterol from building up in their body to cause a heart attack or stroke.
20mg tablet:
20mg tablet is used in the treatment of high cholesterol and triglycerides levels. It works by decreasing the amount of fat, sugar, and cholesterol that are carried in the blood stream. 20 mg tablet contains simeticol which helps to reduce low density lipoprotein (LDL) cholesterol level in human body.
Application Insights:
Adults application segment accounted for the largest share of over 70.0% in 2017. The growing prevalence of cardiovascular diseases and rising awareness about cholesterol-lowering therapy are factors contributing to its large share in the overall market. Furthermore, increasing number of clinical trials supporting its use as a monotherapy for reducing mortality rates associated with CVDs is expected to propel industry growth during the forecast period.
The children application segment is expected to witness substantial growth during the forecast period owing to rising awareness about cholesterol levels among parents and pediatricians coupled with an increase in Pravastatin Sodium Tablets (PRASTO) prescription by pediatricians for treating high cholesterol levels in children below 12 years of age. In addition, increasing incidences such as juvenile hyperlipidemia will drive demand further driving towards higher revenue generation during this forecast period (2016 - 2030).
Regional Analysis:
Asia Pacific was the largest market in 2016 and is expected to continue its dominance over the forecast period. The region accounted for a share of more than 50% in 2016 owing to high demand for cholesterol-lowering drugs from countries, such as China, India, Japan and South Korea. In addition, rising prevalence of cardiovascular diseases and growing awareness about personal health are some other factors driving regional market growth.
Europe is anticipated to be the fastest-growing region during the forecast period due to increasing geriatric population base coupled with rising incidence of lifestyle diseases like diabetes that require long term treatment with statins. Moreover, new product launches by manufacturers including Pravastatin Sodium Tablets 20 mg; Lipostat Co Ltd.; Pravachol Pharmaceuticals Pvt Ltd.; Cipla Inc.; Dr Reddy's Laboratories; Sun Pharmaceutical Industries Limited; GSK; Pfizer Inc.; Merck & Co., Inc., will further boost regional growth over the coming years.
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) due to changing lifestyle and dietary habits.
- Growing geriatric population susceptible to CVDs.
- Rising awareness about the benefits of Pravastatin in preventing CVDs.
- Availability of generic versions of Pravastatin at affordable prices.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pravastatin Market Research Report
By Type
10mg tablet, 20mg tablet, 40mg tablet, 80mg tablet
By Application
Adults, Children
By Companies
Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals, Glenmark, Mylan, Aurobindo Pharma, Accord Healthcare, Upsher-Smith Laboratories, Hisun, Jiangxi Boyaseehot Pharmaceutical, Shanghai Shyndec Pharmaceutical, Daiichi Sankyo, North China Pharmaceutical Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Pravastatin Market Report Segments:
The global Pravastatin market is segmented on the basis of:
Types
10mg tablet, 20mg tablet, 40mg tablet, 80mg tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- TEVA
- SANDOZ
- APOTEX
- Dr. Reddy's Laboratories
- Zydus Pharmaceuticals
- Cipla Inc.
- Lupin Pharmaceuticals
- Glenmark
- Mylan
- Aurobindo Pharma
- Accord Healthcare
- Upsher-Smith Laboratories
- Hisun
- Jiangxi Boyaseehot Pharmaceutical
- Shanghai Shyndec Pharmaceutical
- Daiichi Sankyo
- North China Pharmaceutical Group
Highlights of The Pravastatin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10mg tablet
- 20mg tablet
- 40mg tablet
- 80mg tablet
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pravastatin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pravastatin is a cholesterol-lowering medication that was originally developed as an anti-inflammatory agent. It is now also used to reduce the risk of heart disease and stroke. Pravastatin works by reducing the amount of cholesterol in your blood.
Some of the major players in the pravastatin market are Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals, Glenmark, Mylan, Aurobindo Pharma, Accord Healthcare, Upsher-Smith Laboratories, Hisun, Jiangxi Boyaseehot Pharmaceutical, Shanghai Shyndec Pharmaceutical, Daiichi Sankyo, North China Pharmaceutical Group.
The pravastatin market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pravastatin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pravastatin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pravastatin Market - Supply Chain
4.5. Global Pravastatin Market Forecast
4.5.1. Pravastatin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pravastatin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pravastatin Market Absolute $ Opportunity
5. Global Pravastatin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pravastatin Market Size and Volume Forecast by Type
5.3.1. 10mg tablet
5.3.2. 20mg tablet
5.3.3. 40mg tablet
5.3.4. 80mg tablet
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pravastatin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pravastatin Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pravastatin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pravastatin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pravastatin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pravastatin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pravastatin Demand Share Forecast, 2019-2029
9. North America Pravastatin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pravastatin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pravastatin Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pravastatin Market Size and Volume Forecast by Type
9.7.1. 10mg tablet
9.7.2. 20mg tablet
9.7.3. 40mg tablet
9.7.4. 80mg tablet
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pravastatin Demand Share Forecast, 2019-2029
10. Latin America Pravastatin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pravastatin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pravastatin Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pravastatin Market Size and Volume Forecast by Type
10.7.1. 10mg tablet
10.7.2. 20mg tablet
10.7.3. 40mg tablet
10.7.4. 80mg tablet
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pravastatin Demand Share Forecast, 2019-2029
11. Europe Pravastatin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pravastatin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pravastatin Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pravastatin Market Size and Volume Forecast by Type
11.7.1. 10mg tablet
11.7.2. 20mg tablet
11.7.3. 40mg tablet
11.7.4. 80mg tablet
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pravastatin Demand Share, 2019-2029
12. Asia Pacific Pravastatin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pravastatin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pravastatin Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pravastatin Market Size and Volume Forecast by Type
12.7.1. 10mg tablet
12.7.2. 20mg tablet
12.7.3. 40mg tablet
12.7.4. 80mg tablet
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pravastatin Demand Share, 2019-2029
13. Middle East & Africa Pravastatin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pravastatin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pravastatin Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pravastatin Market Size and Volume Forecast by Type
13.7.1. 10mg tablet
13.7.2. 20mg tablet
13.7.3. 40mg tablet
13.7.4. 80mg tablet
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pravastatin Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Pravastatin Market: Market Share Analysis
14.2. Pravastatin Distributors and Customers
14.3. Pravastatin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. TEVA
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. SANDOZ
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. APOTEX
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dr. Reddy's Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Zydus Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cipla Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lupin Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Glenmark
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Aurobindo Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Accord Healthcare
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Upsher-Smith Laboratories
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Hisun
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Jiangxi Boyaseehot Pharmaceutical
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Shanghai Shyndec Pharmaceutical
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Daiichi Sankyo
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. North China Pharmaceutical Group
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
